Ascletis starts U.S. trial of oral amylin peptide ASC36 for obesity

Ascletis Pharma announced on September 8 that it had initiated a U.S. Phase 1 study of ASC36, an oral amylin receptor peptide agonist being developed for obesity. The study brings the tablet formulation into human testing, where researchers must establish whether its early promise is accompanied by acceptable safety and measurable drug exposure.

The company said the trial followed recent clearance of an investigational new drug application by the Food and Drug Administration. Its announcement contained no human weight-loss results. For the obesity pipeline, the immediate significance is a new formulation entering clinical evaluation; its eventual clinical value remains unknown.

What the study will measure

According to Ascletis, the study is designed to enroll 86 participants with obesity or overweight. It will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple ascending oral doses. Those assessments examine adverse effects, how the body absorbs and processes the drug, and its biological activity.

The announcement does not provide a detailed endpoint hierarchy, allocation scheme or results timetable. Consequently, it does not support describing the study as a randomized efficacy trial or predicting when a reliable estimate of weight loss will become available.

FDA describes Phase 1 research as closely monitored testing that helps establish how an investigational drug interacts with people. Such studies can reveal early activity, but their central role is to gather information that supports the design of subsequent trials.

Animal findings preceded this announcement

ASC36’s preclinical findings were already described in Ascletis’s 2025 annual report, filed in April 2026. That chronology matters: the September development is the announced start of the oral clinical study, rather than newly disclosed proof of effectiveness.

The annual report described experiments in nonhuman primates in which the tablet formulation achieved oral bioavailability of 6% to 8% at steady state. Bioavailability describes the proportion of an administered drug that reaches the circulation. The company also reported reduced food intake and body weight in those animals.

These observations provide a rationale for investigating the formulation. They cannot establish how consistently people will absorb it, whether tolerability will permit sustained treatment, or how much weight participants might lose. Likewise, comparisons with other investigational compounds in animal models cannot establish clinical superiority.

The report identified the company’s proprietary oral delivery technology as part of the formulation’s development. Whether that approach produces useful and reproducible exposure in humans is therefore one of the practical questions behind the clinical program.

What clearance establishes

An investigational new drug application is part of the pathway to testing an unapproved medicine in people. FDA’s explanation of that process specifies animal and toxicity data, manufacturing information and clinical protocols among the materials sponsors submit.

Permission to proceed with research is distinct from marketing approval. FDA’s development framework places clinical testing before the later review of evidence supporting a decision on whether a medicine can be marketed. Ascletis’s statement about clearance should therefore be read as a development milestone, without implying an FDA determination that ASC36 treats obesity effectively.

For readers following metabolic health and healthspan, the meaningful next evidence would be human safety and exposure results, followed by adequately controlled studies of sustained benefit. Larger and longer trials are also better positioned to identify uncommon or delayed adverse effects. This announcement offers no evidence about cardiovascular outcomes, disability, healthy lifespan or long-term weight maintenance.